Agios Pharmaceuticals, Inc. - Common Stock (AGIO)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 24, 2026Investment Snapshot
- Trading 60% below Graham Number ($70.92) — significant margin of safety
- Piotroski F-Score 3/9 — signs of financial weakness
- Strong ROE of 53.9% with 1,494.9% net margin
- Revenue growing at 48% annually
Agios Pharmaceuticals, Inc. - Common Stock (AGIO) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1.6 billion . Key value metrics: P/E ratio 2.6, P/B ratio 1.38, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Agios Pharmaceuticals, Inc. - Common Stock — Fundamental Analysis Summary
Agios Pharmaceuticals, Inc. - Common Stock (AGIO) is trading 60% below its Graham Number of $70.92 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 2.6x.
On financial health, AGIO shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and strong return on equity of 53.9% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.09.
StockPik's composite Value Score for AGIO is 82/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
AGIO reports a high gross margin of 87.8% (sector average: 33.5%) and a negative operating margin of -1,053.7%.
AGIO shows revenue growing at 48% year-over-year, with earnings declining at 161%.